Penwest Files Definitive Proxy Materials in Connection With June 10 Annual Meeting
07 mai 2009 13h30 HE
|
Penwest Pharmaceuticals Co.
DANBURY, Conn., May 7, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) announced today that it has filed its definitive proxy statement with the U.S. Securities and Exchange...
Penwest Reports First Quarter 2009 Financial Results
07 mai 2009 08h00 HE
|
Penwest Pharmaceuticals Co.
DANBURY, Conn., May 7, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today announced its financial results for the first quarter of 2009. Compared with the first quarter of 2008,...
Penwest First Quarter 2009 Financial Results Conference Call
29 avr. 2009 13h00 HE
|
Penwest Pharmaceuticals Co.
DANBURY, Conn., April 29, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) will conduct a conference call on Thursday, May 7, 2009, at 11:00 a.m. EDT to review its financial results...
Penwest Sends Letter to Shareholders On Financial, Business and Corporate Governance Developments
12 mars 2009 08h00 HE
|
Penwest Pharmaceuticals Co.
DANBURY, Conn., March 12, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today sent a letter to its shareholders in which the Company provided an update on its recent financial and...
Penwest to Present At Cowen & Company 29th Annual Healthcare Conference
11 mars 2009 09h30 HE
|
Penwest Pharmaceuticals Co.
DANBURY, Conn., March 11, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today announced that Jennifer Good, President and Chief Executive Officer of Penwest, will be presenting at...
Penwest Reports Fourth Quarter and Year End 2008 Financial Results
04 mars 2009 07h30 HE
|
Penwest Pharmaceuticals Co.
Operating Costs Reduced by 30%
2009 Guidance for Revenues of $22 Million to $24 Million and for
Net Loss of $1 Million to $3 Million Reflects Increased Royalties From
...
Penwest Begins Phase Ib Clinical Trial of A0001, Dosing Underway of Compound for the Treatment of Mitochondrial Diseases
25 févr. 2009 08h00 HE
|
Penwest Pharmaceuticals Co.
DANBURY, Conn., Feb. 25, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today announced that it has begun dosing in a Phase Ib clinical trial of A0001, a compound the Company is...
Penwest Fourth Quarter and Year End 2008 Financial Results Conference Call
23 févr. 2009 12h05 HE
|
Penwest Pharmaceuticals Co.
DANBURY, Conn., Feb. 23, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) will conduct a conference call on Wednesday, March 4, at 11:00 a.m. EST to review its financial results for...
Penwest to Present At 11th Annual BIO CEO & Investor Conference
04 févr. 2009 16h15 HE
|
Penwest Pharmaceuticals Co.
DANBURY, Conn., Feb. 4, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today announced that Jennifer Good, President and Chief Executive Officer of Penwest, will be presenting at...
Penwest Sets Focused Priorities for 2009; Takes Actions to Further Reduce Costs
22 janv. 2009 16h15 HE
|
Penwest Pharmaceuticals Co.
DANBURY, Conn., Jan. 22, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today announced that its Board of Directors and senior management have set narrowed priorities for 2009, and...